Controlled document PF-021A
InflammaSacra II Master Formula
Record identification
- Document ID
- PF-021A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-021A
PRODUCT FORMULA CARD
SIRIAM INFLAMMASACRA II
TRANSITUS
Neurovegetative Integration Phase
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Family
Therapeutic Phase
Clinical Stage
Product Type
Standard Batch
Version
Status
| Value |
|---|
| SIR-INF-002 |
| MF-021 |
| PF-021A |
| InflammaSacra II |
| InflammaSacra™ |
| TRANSITUS |
| 6 weeks – 3 months |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
1. PRODUCT PURPOSE
Field
Clinical Objective
Primary Biological Target
Therapeutic Phase
Clinical Stage
The magistral fiche describes InflammaSacra II as the transition phase from inflammatory activation to recovery and integration, with emphasis on orthosympathetic-to-parasympathetic shift, microcirculation and fascial integration.
| Description |
|---|
| Neurodermal and neurovegetative transition from inflammatory activation toward tissue recovery |
| Microcirculation, autonomic regulation and fascial integration |
| TRANSITUS |
| Subacute (6 weeks–3 months) |
2. MASTER FORMULA
The ingredient list follows the magistral fiche for InflammaSacra II, with the previously agreed SQMS naming standard (Vitamin E Full Spectrum and Silicea Gel + Silicea D8).
| Code |
|---|
| Official Ingredient |
| Current |
| Proposed |
| Unit |
| PC-001 |
| Lanette Cream FNA |
| 67.00 |
| g |
| PC-002 |
| Aqua Purificata |
| 16.00 |
| g |
| SC-001 |
| Magnesium Chloride |
| 2.00 |
| g |
| SC-002 |
| MSM |
| 1.50 |
| g |
| AC-003 |
| Palmitoylethanolamide (PEA) |
| 1.00 |
| g |
| AC-005 |
| Niacinamide |
| 1.00 |
| g |
| SC-003 |
| D-Panthenol |
| 1.00 |
| g |
| AC-010 |
| Quercetin |
| 0.50 |
| g |
| AC-011 |
| Zinc Bisglycinate |
| 0.50 |
| g |
| BE-001 |
| Boswellia serrata |
| 0.50 |
| g |
| BE-003 |
| Ginkgo biloba |
| 0.50 |
| g |
| BE-004 |
| Bacopa monnieri |
| 0.50 |
| mL |
| BE-016 |
| Withania somnifera (Ashwagandha) |
| 0.30 |
| mL |
| BE-002 |
| Copaiba Oil |
| 0.40 |
| g |
| AC-006 |
| α-Bisabolol |
| 0.25 |
| g |
| SC-004 |
| Vitamin E Full Spectrum |
| 0.70 |
| g |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| 2.50 |
| g |
| AC-002 |
| Betaine (TMG) |
| 0.50 |
| g |
| PR-001 |
| Cosgard 221 |
| 0.70 |
| g |
| HC-010 |
| Silicea D8 |
| 10 |
| drops |
| HC-011 |
| Fluorite D12 |
| 10 |
| drops |
| BE-008 |
| Arnica montana D8 |
| 3 |
| drops |
| BE-010 |
| Hypericum perforatum D6 |
| 3 |
| drops |
| HC-012 |
| GUNA NGF 4CH |
| 5 |
| drops |
| HC-013 |
| GUNA EGF 4CH |
| 5 |
| drops |
| BE-005 |
| Nymphaea caerulea Essence |
| 1 |
| drop |
3. MANUFACTURING WORKFLOW
Standard SQMS Lanette Manufacturing Workflow.
Special additions:
Bacopa
Ashwagandha
α-Bisabolol
Homeopathic components
added below 35°C.
The Lanette preparation sequence and cooling phase additions are specified in the magistral fiche.
6. CLINICAL APPLICATION
Field
Clinical Stage
Frequency
Primary Goal
EMG Goal
Next Phase
The fiche recommends twice-daily application during the subacute phase with progression to InflammaSacra III after this recovery stage.
| Value |
|---|
| 6 weeks–3 months |
| Twice daily |
| Transition from inflammation to regeneration |
| Reduced residual muscle activity |
| InflammaSacra III |
Related documents
Platform modules